SparX Biopharmaceutical
A US-based, research-driven biopharmaceutical company aiming to amplify human immunity with antibody therapies.
Through the utilization of big data analytics, including machine learning, SparX decrypts potential interactions within the vast complexity of biological information.
SparX's target discovery platform, combined with the SAILING antibody optimization system and bi-ADC technology, aims to redefine antibody drug development. Equipped with in-house cGMP facilities,
Latest SparX Biopharmaceutical News & Features
17 October 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze